Should You Buy Immunovant Inc (IMVT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
26.450
1 Day change
1.50%
52 Week Range
27.800
Analysis Updated At
2026/01/29
Immunovant Inc (IMVT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown some positive momentum in the short term and hedge funds are buying, the lack of strong financial performance, no significant news catalysts, and mixed technical indicators suggest that it is better to hold off on investing right now.
Technical Analysis
The stock's moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. However, the MACD is below zero and negatively contracting, and the RSI is neutral at 53.316, showing no clear signal. The stock is trading near its pivot level of 26.332, with resistance at 27.149 and support at 25.515.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The low put-call ratios indicate a bullish sentiment in the options market, with more interest in calls than puts. However, the implied volatility is high (83.98), suggesting elevated risk.
Technical Summary
Sell
1
Buy
12
Positive Catalysts
Hedge funds are significantly increasing their buying activity, up 133.13% over the last quarter. Analysts have recently upgraded the stock, with Wolfe Research moving it to Outperform. The company has an extended cash runway due to a recent equity raise.
Neutral/Negative Catalysts
The company's financials remain weak, with no revenue growth and a net loss of -$126.5M in the latest quarter. EPS dropped by -1.35% YoY. There is no recent news or significant insider trading activity to act as a catalyst.
Financial Performance
In Q2 2026, the company reported no revenue growth (0% YoY) and a net loss of -$126.5M, which improved by 15.93% YoY. EPS dropped slightly to -0.73 (-1.35% YoY). Gross margin remains at 0%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts have mixed views. Truist raised the price target to $22 from $16 but maintained a Hold rating. Wolfe Research upgraded the stock to Outperform. Guggenheim lowered the price target to $41 from $44 but maintained a Buy rating, citing dilution from a recent equity raise.
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37 USD with a low forecast of 22 USD and a high forecast of 54 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37 USD with a low forecast of 22 USD and a high forecast of 54 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 26.060
Low
22
Averages
37
High
54
Current: 26.060
Low
22
Averages
37
High
54
Truist
Danielle Brill
Hold
maintain
$16 -> $22
AI Analysis
2026-01-08
Reason
Truist
Danielle Brill
Price Target
$16 -> $22
AI Analysis
2026-01-08
maintain
Hold
Reason
Truist analyst Danielle Brill raised the firm's price target on Immunovant to $22 from $16 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Wolfe Research
Andy Chen
Peer Perform -> Outperform
upgrade
2026-01-06
Reason
Wolfe Research
Andy Chen
Price Target
2026-01-06
upgrade
Peer Perform -> Outperform
Reason
Wolfe Research analyst Andy Chen upgraded Immunovant to Outperform from Peer Perform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMVT
